header logo image

Glaucoma Therapeutics The market is expected to see a surge in growth | Allergan , Merck , Novartis – The Courier

December 16th, 2020 1:53 am

Glaucoma refers to the group of conditions characterized by optic nerve damage, visual field loss, and secondary to retinal ganglion cell damage, which may lead to death. According to the International Agency for the Prevention of Blindness: 2016, glaucoma is second leading cause of blindness and leading cause of irreversible blindness worldwide. The most common types of glaucoma are Primary Open Angle Glaucoma (POAG) and Primary Angle Closure Glaucoma (PACG). Moreover, PACG is most common in South-East Asian population while POAG is most common in white Caucasians and individuals of African origin. PACG is associated with a high risk of blindness as compared to POAG.

Glaucoma is a group of eye diseases which result in damage to the optic nerve and cause vision loss. The most common type is open-angle (wide angle, chronic simple) glaucoma, in which the drainage angle for fluid within the eye remains open, with less common types including closed-angle (narrow angle, acute congestive) glaucoma and normal-tension glaucoma. Open-angle glaucoma develops slowly over time and there is no pain. Peripheral vision may begin to decrease, followed by central vision, resulting in blindness if not treated. Closed-angle glaucoma can present gradually or suddenly. The sudden presentation may involve severe eye pain, blurred vision, mid-dilated pupil, redness of the eye, and nausea. Vision loss from glaucoma, once it has occurred, is permanent. Eyes affected by glaucoma are referred to as being glaucomatous.

Apply For Sample Report (Get Full Insights in PDF) with Tables, Charts, and Graphs: https://www.worldwidemarketreports.com/sample/311182

By Top Industry Players:Allergan ,Merck ,Novartis ,Pfizer ,Santen Pharmaceuticals ,Valeant Pharmaceuticals

Risk factors for glaucoma include increasing age, high pressure in the eye, a family history of glaucoma, and use of steroid medication. For eye pressures, a value of greater than 21 mmHg or 2.8 kPa is often used, with higher pressures leading to a greater risk. However, some may have high eye pressure for years and never develop damage. Conversely, optic nerve damage may occur with normal pressure, known as normal-tension glaucoma. The mechanism of open-angle glaucoma is believed to be slow exit of aqueous humor through the trabecular meshwork, while in closed-angle glaucoma the iris blocks the trabecular meshwork. Diagnosis is by a dilated eye examination.Often, the optic nerve shows an abnormal amount of cupping.

If treated early, it is possible to slow or stop the progression of disease with medication, laser treatment, or surgery. The goal of these treatments is to decrease eye pressure. A number of different classes of glaucoma medication are available. Laser treatments may be effective in both open-angle and closed-angle glaucoma. A number of types of glaucoma surgeries may be used in people who do not respond sufficiently to other measures. Treatment of closed-angle glaucoma is a medical emergency.

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.):

ProstaglandinsAlpha AgonistBeta BlockersCarbonic Anhydrase InhibitorCholinergicCombined Medication

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

HospitalsOphthalmic ClinicsAmbulatory Surgical Centers

Thanks for your visit. If you have any other questions, please contact us. Our team will prepare a report tailored to your needs.

https://www.worldwidemarketreports.com/quiry/311182

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email:sales@worldwidemarketreports.com

More:
Glaucoma Therapeutics The market is expected to see a surge in growth | Allergan , Merck , Novartis - The Courier

Related Post

Comments are closed.


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick